相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function
Susanne Adam et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis
Christian S. Thudium et al.
ARTHRITIS RESEARCH & THERAPY (2020)
Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial
Peter C. Taylor et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM
Bruno Fautrel et al.
JOURNAL OF CLINICAL MEDICINE (2019)
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis
Charles Peterfy et al.
JOURNAL OF RHEUMATOLOGY (2019)
Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis
Desiree van Der Heijde et al.
RMD OPEN (2019)
Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis
Anne C. Bay-Jensen et al.
BMC RHEUMATOLOGY (2019)
Low Hemoglobin and Radiographic Damage Progression in Early Rheumatoid Arthritis: Secondary Analysis From a Phase III Trial
Burkhard Moeller et al.
ARTHRITIS CARE & RESEARCH (2018)
Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study
Desiree van der Heijde et al.
CLINICAL RHEUMATOLOGY (2018)
Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics
Joel M. Kremer et al.
RMD OPEN (2018)
Radiographic progression in early rheumatoid arthritis patients following initial combination versus step-up treat-to-target therapy in daily clinical practice: results from the DREAM registry
Laura M. M. Steunebrink et al.
BMC RHEUMATOLOGY (2018)
Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
Maxime Dougados et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Peter C. Taylor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro
Kohei Murakami et al.
PLOS ONE (2017)
Cellular and molecular pathways of structural damage in rheumatoid arthritis
Ulrike Harre et al.
SEMINARS IN IMMUNOPATHOLOGY (2017)
Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment
Roy Fleischmann et al.
ARTHRITIS & RHEUMATOLOGY (2017)
Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis
Paul Emery et al.
RMD OPEN (2017)
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study
Edward C. Keystone et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment
Michael Schiff et al.
ARTHRITIS RESEARCH & THERAPY (2017)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
John J. O'Shea et al.
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
Anaemia may add information to standardised disease activity assessment to predict radiographic damage in rheumatoid arthritis: a prospective cohort study
Burkhard Moeller et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Greater body mass independently predicts less radiographic progression on X-ray and MRI over 1-2 years
Joshua F. Baker et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs
Jun Hashimoto et al.
Modern Rheumatology (2014)
Early Local Swelling and Tenderness Are Associated with Large-joint Damage After 8 Years of Treatment to Target in Patients with Recent-onset Rheumatoid Arthritis
Marianne van den Broek et al.
JOURNAL OF RHEUMATOLOGY (2013)
Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis
John D. Isaacs et al.
ARTHRITIS RESEARCH & THERAPY (2013)
Evaluating joint-space narrowing and cartilage loss in rheumatoid arthritis by using MRI
Charles G. Peterfy et al.
ARTHRITIS RESEARCH & THERAPY (2012)
Predicting arthritis outcomes-what can be learned from the Leiden Early Arthritis Clinic?
Diederik P. C. de Rooy et al.
RHEUMATOLOGY (2011)
Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050
Jordan S. Fridman et al.
JOURNAL OF IMMUNOLOGY (2010)
Interleukin-6 as a key player in systemic inflammation and joint destruction
J. E. Fonseca et al.
AUTOIMMUNITY REVIEWS (2009)
Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change
K Bruynesteyn et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
分享论文
